Consistent international data positions Nu.Q® H3.1 as a potential "game changer" in sepsis management within a $3.8 billion addressable market
HENDERSON, Nev., July 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive update highlighting the significant clinical and scientific evidence amassed for its Nu.Q® NETs product. It also issued a video featuring Critical Care Lead and Medical Consultant to Volition, Dr Andrew Retter, who explains the scientific and clinical significance of these findings.
-->